Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Neoplasm Metastasis TAMK (TAM kinase) MER (mer proto-oncogene) MERTK (mer proto-oncogene tyrosine kinase) AXL (AXL receptor tyrosine kinase) AXL/MER Selective kinase inhibitor PD-1 (programmed cell death protein 1) PD-L1 (programmed cell death ligand 1) Immune modulator Advanced Cancer Metastatic Cancer Solid Tumor Cancer Metastatic Solid Tumor Cervical Cancer Gastric Cancer Esophageal Cancer Endometrial Cancer Hepatocellular carcinoma (HCC) Melanoma Merkel Cell Carcinoma High levels of MicroSatellite Instability deficient MisMatch Repair (MSI-H-dMMR) tumor Non-small cell lung cancer (NSCLC) Small cell lung cancer (SCLC) Renal cell carcinoma (RCC) Urothelial carcinoma Colorectal cancer (CRC) Axitinib Sasanlimab
Lead Scientist at UCSF
- Adil Daud
Professor, Medicine, School of Medicine. Authored (or co-authored) 190 research publications
- accepting new patients
- Start Date
- Completion Date
- To obtain contact information for a study center near you, click here.
- Phase 1 research study
- Study Type
- Expecting 155 study participants
- Last Updated